entertainment -WSS

entertainment

author：comprehensive 2025-10-01 00:06:26 - browse：612

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

explore

WSS

Where does female orgasm come from? Scientists think they know

BD to buy Edwards patient monitoring unit for $4.2 billion

Congress needs to close a vaccine

Statins reduce cardiovascular risk in people living with HIV

Medicare Advantage's lean provider networks lead CMS complaints

Fight over Supreme Court dialysis ruling puts kidney patients at risk

knowledge

entertainment

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Senators tussle over abortion against the backdrop of a presidential campaign

Trump demands the U.S. pay no more for drugs than other countries … again

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly’s Zepbound improved liver scarring in mid

Duchenne breakthrough therapy leaves behind pioneering families

Malaysia cuts short music fest after British band slams anti

Medicare details structure of new drug price negotiation program

FTC loses bid to block Novant's North Carolina hospital merger

explore

FDA approves Moderna’s RSV vaccine, its second licensed product

Severe heat forecast: Where scorching temperatures will persist over the next week

ASCO Daily Recap: CAR

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Where does female orgasm come from? Scientists think they know

New requirements coming in 2024 for Americans traveling to Europe

explore

focus

explore

Wikipedia